Korro Bio, Inc. Capital Expenditures Incurred but Not yet Paid
Korro Bio, Inc. (KRRO) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2022-08-09
- Korro Bio, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was $0.00.
- Korro Bio, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. capital expenditures incurred but not yet paid for the quarter ending 2021-09-30 was -$726.00K.
- Korro Bio, Inc. capital expenditures incurred but not yet paid for the quarter ending 2021-06-30 was -$1.03M.
- Korro Bio, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $2.15M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 6 month as first filed | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | ||||
| 2021-09-30 | -$726.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$1.76M derived: sum of 2 quarters · filed 2022-08-09 | $34.00K 10-Q · filed 2021-11-15 | $2.15M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-06-30 | -$1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $760.00K 10-Q · filed 2022-08-09 | $12.00K 10-Q · filed 2021-08-12 | $2.88M derived: sum of 3 quarters · filed 2022-08-09 | $2.71M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.79M 10-Q · filed 2022-05-04 | $3.91M derived: sum of 2 quarters · filed 2022-05-04 | $3.74M derived: sum of 3 quarters · filed 2022-05-04 | ||
| 2020-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.95M derived: sum of 2 quarters · filed 2022-03-15 | $2.15M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | -$173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $24.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $197.00K 10-Q · filed 2020-08-12 | ||||
| 2019-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $71.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $18.00K 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |